[{"id":"4346ba5f-67b8-4706-8e12-549591ad58c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06696768","created_at":"2025-02-25T20:15:51.863Z","updated_at":"2025-02-25T20:15:51.863Z","phase":"Phase 1","brief_title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06696768","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • IL6 • CCL2 • CXCL1 • IRAK4","pipe":"","alterations":" ","tags":["IFNG • IL6 • CCL2 • CXCL1 • IRAK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • emavusertib (CA-4948) • fluorouracil topical"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-01-16"},{"id":"7751beea-ed0b-4a4d-8397-acffe8af0a14","acronym":"","url":"https://clinicaltrials.gov/study/NCT02432378","created_at":"2021-01-18T11:38:27.441Z","updated_at":"2024-07-02T16:35:00.114Z","phase":"Phase 1/2","brief_title":"Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines","source_id_and_acronym":"NCT02432378","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX","pipe":"","alterations":" ","tags":["IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Suspended","enrollment":" Enrollment 25","initiation":"Initiation: 09/04/2015","start_date":" 09/04/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-30"},{"id":"894d41c8-fa82-4742-ae07-cc5efd0a178a","acronym":"EARDIS","url":"https://clinicaltrials.gov/study/NCT05648240","created_at":"2022-12-13T14:58:01.312Z","updated_at":"2024-07-02T16:35:20.013Z","phase":"","brief_title":"Proof-of-concept Study of Blood Markers of Tumor Dissemination in Patients With Versus Without Intestinal Polyps","source_id_and_acronym":"NCT05648240 - EARDIS","lead_sponsor":"Centre Hospitalier Universitaire de Nīmes","biomarkers":" CXCL12 • TIMP1 • CCL2 • CSF2 • CXCL1","pipe":"","alterations":" ","tags":["CXCL12 • TIMP1 • CCL2 • CSF2 • CXCL1"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 02/23/2023","start_date":" 02/23/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-02-09"},{"id":"88a56803-e53e-402f-8615-d502f691f9f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04682665","created_at":"2021-01-19T20:46:58.736Z","updated_at":"2024-07-02T16:35:27.981Z","phase":"","brief_title":"Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases","source_id_and_acronym":"NCT04682665","lead_sponsor":"University of Leeds","biomarkers":" PD-1 • CTLA4 • TIGIT • CCL2","pipe":"","alterations":" ","tags":["PD-1 • CTLA4 • TIGIT • CCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e icosapent ethyl"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 09/16/2021","start_date":" 09/16/2021","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-11-28"},{"id":"c15a52de-3419-47f0-9b51-09f2e18386cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05964985","created_at":"2023-07-31T17:08:51.096Z","updated_at":"2024-07-02T16:35:41.679Z","phase":"","brief_title":"Effect of Quadratus Lumborum Block With Compound Lidocaine and Esketamine on Pain After Colorectal Surgery","source_id_and_acronym":"NCT05964985","lead_sponsor":"Tianjin Medical University General Hospital","biomarkers":" CCL2 • IL18 • IL17A • IL23A • CXCL1","pipe":"","alterations":" ","tags":["CCL2 • IL18 • IL17A • IL23A • CXCL1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 08/06/2023","start_date":" 08/06/2023","primary_txt":" Primary completion: 01/15/2024","primary_completion_date":" 01/15/2024","study_txt":" Completion: 02/15/2024","study_completion_date":" 02/15/2024","last_update_posted":"2023-07-28"},{"id":"566c9041-7141-4d32-8811-4cba0ea909a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05293041","created_at":"2022-03-24T14:52:49.790Z","updated_at":"2024-07-02T16:35:43.137Z","phase":"Phase 4","brief_title":"Argipressin's Influence on Blood Loss During Hepatic Resection","source_id_and_acronym":"NCT05293041","lead_sponsor":"Kristina Svennerholm","biomarkers":" IL6 • CXCL12 • IL10 • CCL2 • TIMP2 • IGFBP7","pipe":"","alterations":" ","tags":["IL6 • CXCL12 • IL10 • CCL2 • TIMP2 • IGFBP7"],"overall_status":"Recruiting","enrollment":" Enrollment 248","initiation":"Initiation: 03/27/2022","start_date":" 03/27/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-07-13"},{"id":"23758911-8745-4e04-b970-f675198d8588","acronym":"PRINCESS","url":"https://clinicaltrials.gov/study/NCT05821751","created_at":"2023-04-20T14:03:53.992Z","updated_at":"2024-07-02T16:35:50.012Z","phase":"","brief_title":"The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT05821751 - PRINCESS","lead_sponsor":"Fondazione del Piemonte per l'Oncologia","biomarkers":" PD-L1 • PD-1 • IL6 • LAG3 • CXCL8 • CXCL10 • HAVCR2 • IL2 • ICOS • IL10 • CCL2 • IL13 • IL15 • IL21 • IL4 • IL5","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • IL6 • LAG3 • CXCL8 • CXCL10 • HAVCR2 • IL2 • ICOS • IL10 • CCL2 • IL13 • IL15 • IL21 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/02/2021","start_date":" 12/02/2021","primary_txt":" Primary completion: 12/02/2024","primary_completion_date":" 12/02/2024","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2023-04-20"},{"id":"30c12ff9-e4f6-4aaa-b23a-ab2e125bc519","acronym":"","url":"https://clinicaltrials.gov/study/NCT03392584","created_at":"2021-11-18T23:54:56.929Z","updated_at":"2024-07-02T16:35:51.638Z","phase":"","brief_title":"Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters","source_id_and_acronym":"NCT03392584","lead_sponsor":"Oslo University Hospital","biomarkers":" VEGFA • IL6 • CXCL10 • IL2 • IL10 • CCL2 • FGF • IL17A","pipe":"","alterations":" ","tags":["VEGFA • IL6 • CXCL10 • IL2 • IL10 • CCL2 • FGF • IL17A"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 01/08/2022","study_completion_date":" 01/08/2022","last_update_posted":"2023-04-03"},{"id":"96c1a79b-dc4c-4532-bdcc-568aae7c4193","acronym":"","url":"https://clinicaltrials.gov/study/NCT05176691","created_at":"2022-01-04T13:53:37.587Z","updated_at":"2024-07-02T16:35:55.163Z","phase":"Phase 1","brief_title":"HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL","source_id_and_acronym":"NCT05176691","lead_sponsor":"Hutchmed","biomarkers":" CCL2","pipe":"","alterations":" ","tags":["CCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HMPL-760"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/15/2022","start_date":" 02/15/2022","primary_txt":" Primary completion: 11/16/2022","primary_completion_date":" 11/16/2022","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2023-02-20"},{"id":"398611ec-32d5-4767-9ab0-d167a02f0c96","acronym":"ICE","url":"https://clinicaltrials.gov/study/NCT05727813","created_at":"2023-02-14T18:02:36.078Z","updated_at":"2024-07-02T16:35:55.606Z","phase":"","brief_title":"To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study)","source_id_and_acronym":"NCT05727813 - ICE","lead_sponsor":"University of Roma La Sapienza","biomarkers":" IL6 • CXCL8 • IL2RA • CXCL9 • IL10 • HMGB1 • CCL11 • CCL2 • IL17A • CCL3 • IL13 • IL15 • IL1R1 • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2RA • CXCL9 • IL10 • HMGB1 • CCL11 • CCL2 • IL17A • CCL3 • IL13 • IL15 • IL1R1 • IL4 • IL5 • IL7"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 01/16/2023","primary_completion_date":" 01/16/2023","study_txt":" Completion: 01/27/2023","study_completion_date":" 01/27/2023","last_update_posted":"2023-02-14"},{"id":"0c90cd30-d9b5-4626-af27-72cee25782de","acronym":"REBORN","url":"https://clinicaltrials.gov/study/NCT04464122","created_at":"2021-01-18T21:27:30.836Z","updated_at":"2024-07-02T16:36:00.020Z","phase":"","brief_title":"Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","source_id_and_acronym":"NCT04464122 - REBORN","lead_sponsor":"University of Roma La Sapienza","biomarkers":" KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3","pipe":"","alterations":" ","tags":["KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 09/14/2024","primary_completion_date":" 09/14/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-11-23"},{"id":"7d2a47ff-9cf7-49c0-a990-f38b132df74e","acronym":"Agility","url":"https://clinicaltrials.gov/study/NCT05615883","created_at":"2022-11-14T14:58:23.397Z","updated_at":"2024-07-02T16:36:00.503Z","phase":"","brief_title":"Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients","source_id_and_acronym":"NCT05615883 - Agility","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" IL6 • TNFA • CXCL8 • IL10 • CD14 • CCL2 • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL10 • CD14 • CCL2 • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/20/2020","start_date":" 01/20/2020","primary_txt":" Primary completion: 02/28/2023","primary_completion_date":" 02/28/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2022-11-14"},{"id":"024e1277-d133-4914-a627-57cfe108a970","acronym":"TruCulture","url":"https://clinicaltrials.gov/study/NCT04127864","created_at":"2021-01-18T20:09:51.316Z","updated_at":"2024-07-02T16:36:05.964Z","phase":"","brief_title":"Perioperative Immune Function in Patients Undergoing Colorectal Cancer Surgery","source_id_and_acronym":"NCT04127864 - TruCulture","lead_sponsor":"University of Copenhagen","biomarkers":" IL6 • TNFA • CXCL8 • IL2 • IL10 • CCL2 • CSF2 • IL17A • IL13 • IL1B • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL2 • IL10 • CCL2 • CSF2 • IL17A • IL13 • IL1B • IL4 • IL5 • IL7"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/14/2019","start_date":" 10/14/2019","primary_txt":" Primary completion: 12/20/2019","primary_completion_date":" 12/20/2019","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-08-05"},{"id":"110ea52b-e84e-4c4f-ac59-5c89e4d16963","acronym":"EPITHEM","url":"https://clinicaltrials.gov/study/NCT04576429","created_at":"2021-01-18T21:50:49.552Z","updated_at":"2024-07-02T16:36:16.766Z","phase":"","brief_title":"Immune Profiles Evolution Under Immunotherapy for Melanoma","source_id_and_acronym":"NCT04576429 - EPITHEM","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" VEGFA • IFNG • IL6 • TNFA • CXCL10 • IL2 • CCL20 • IL10 • CCL19 • CCL2 • GZMB • IL17A • IL1A • IFNA1 • IL1B • IL1RN • TGFA • TNFSF10 • CXCL1 • IL33","pipe":"","alterations":" ","tags":["VEGFA • IFNG • IL6 • TNFA • CXCL10 • IL2 • CCL20 • IL10 • CCL19 • CCL2 • GZMB • IL17A • IL1A • IFNA1 • IL1B • IL1RN • TGFA • TNFSF10 • CXCL1 • IL33"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 01/01/2031","primary_completion_date":" 01/01/2031","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2022-02-23"},{"id":"acaf9a0f-a467-43c2-8f34-dc61f9d4f9d3","acronym":"OMICC","url":"https://clinicaltrials.gov/study/NCT03661047","created_at":"2021-01-18T17:57:51.957Z","updated_at":"2024-07-02T16:36:20.624Z","phase":"Phase 2","brief_title":"OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer","source_id_and_acronym":"NCT03661047 - OMICC","lead_sponsor":"Massachusetts General Hospital","biomarkers":" PD-L1 • CD8 • PD-1 • IL6 • LAG3 • TNFA • CTLA4 • HAVCR2 • TIGIT • IL10 • CCL2 • FOXP3 • ITGA2","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • PD-1 • IL6 • LAG3 • TNFA • CTLA4 • HAVCR2 • TIGIT • IL10 • CCL2 • FOXP3 • ITGA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e icosapent ethyl"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2019","start_date":" 11/30/2019","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 11/30/2021","study_completion_date":" 11/30/2021","last_update_posted":"2021-11-17"},{"id":"5a88e172-f3f1-4d49-981a-f074496e0ad9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05122338","created_at":"2021-11-16T12:53:42.048Z","updated_at":"2024-07-02T16:36:20.673Z","phase":"","brief_title":"Effect of Transversus Abdominis Plane Block With Compound Lidocaine and Esketamine on Pain After Surgery","source_id_and_acronym":"NCT05122338","lead_sponsor":"Tianjin Medical University General Hospital","biomarkers":" CCL2 • IL18 • IL17A • IL23A • CXCL1","pipe":"","alterations":" ","tags":["CCL2 • IL18 • IL17A • IL23A • CXCL1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 05/15/2022","primary_completion_date":" 05/15/2022","study_txt":" Completion: 06/15/2022","study_completion_date":" 06/15/2022","last_update_posted":"2021-11-16"},{"id":"56eaeae2-1ec3-449e-8c3a-81f7351b0c9c","acronym":"Cytokim-01","url":"https://clinicaltrials.gov/study/NCT04928365","created_at":"2021-06-16T18:52:48.657Z","updated_at":"2024-07-02T16:36:28.995Z","phase":"Phase 2","brief_title":"Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy","source_id_and_acronym":"NCT04928365 - Cytokim-01","lead_sponsor":"Blokhin's Russian Cancer Research Center","biomarkers":" VEGFA • IFNG • IL6 • CXCL10 • CXCL9 • IL2 • IL10 • CCL2 • IL22","pipe":"","alterations":" ","tags":["VEGFA • IFNG • IL6 • CXCL10 • CXCL9 • IL2 • IL10 • CCL2 • IL22"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/25/2021","start_date":" 03/25/2021","primary_txt":" Primary completion: 05/11/2021","primary_completion_date":" 05/11/2021","study_txt":" Completion: 03/25/2023","study_completion_date":" 03/25/2023","last_update_posted":"2021-06-16"},{"id":"1a78ec6a-4783-4856-99e9-df1f45fe8f9c","acronym":"AFGBM1","url":"https://clinicaltrials.gov/study/NCT04116138","created_at":"2021-01-18T20:07:12.416Z","updated_at":"2024-07-02T16:36:31.045Z","phase":"Phase 1/2","brief_title":"Antisecretory Factor in Primary Glioblastoma 1","source_id_and_acronym":"NCT04116138 - AFGBM1","lead_sponsor":"Peter Siesjö","biomarkers":" IL6 • CCL2","pipe":"","alterations":" ","tags":["IL6 • CCL2"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 03/31/2021","study_completion_date":" 03/31/2021","last_update_posted":"2021-04-28"},{"id":"86454e03-0e85-49fd-ab55-01ed8e65ac8b","acronym":"JAVELIN Solid Tumor JPN","url":"https://clinicaltrials.gov/study/NCT01943461","created_at":"2021-01-18T08:48:08.113Z","updated_at":"2025-02-25T14:49:45.257Z","phase":"Phase 1","brief_title":"Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)","source_id_and_acronym":"NCT01943461 - JAVELIN Solid Tumor JPN","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • CCL2 • IL1B","pipe":" | ","alterations":" PD-L1 expression","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • CCL2 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 09/02/2013","start_date":" 09/02/2013","primary_txt":" Primary completion: 01/07/2015","primary_completion_date":" 01/07/2015","study_txt":" Completion: 09/25/2019","study_completion_date":" 09/25/2019","last_update_posted":"2020-09-30"},{"id":"e90d90e5-33e6-4be3-bd2c-8d8dccd30023","acronym":"","url":"https://clinicaltrials.gov/study/NCT04355806","created_at":"2021-01-18T21:03:23.571Z","updated_at":"2024-07-02T16:36:45.824Z","phase":"","brief_title":"Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors","source_id_and_acronym":"NCT04355806","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" CD8 • IFNG • IL6 • TNFA • CXCL8 • CXCL10 • CD4 • CD69 • IL2 • IL10 • CCL2 • CSF2 • IL13 • IL1B • IL4 • IL5","pipe":" | ","alterations":" CD8 expression","tags":["CD8 • IFNG • IL6 • TNFA • CXCL8 • CXCL10 • CD4 • CD69 • IL2 • IL10 • CCL2 • CSF2 • IL13 • IL1B • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2020-04-21"},{"id":"1b538d58-e69e-4cb2-88ca-91d1700ceaba","acronym":"BIOMOG","url":"https://clinicaltrials.gov/study/NCT04202055","created_at":"2021-01-18T20:28:28.008Z","updated_at":"2024-07-02T16:36:52.321Z","phase":"","brief_title":"Immunologic Biomarker Profile of Cerebrospinal Fluid","source_id_and_acronym":"NCT04202055 - BIOMOG","lead_sponsor":"Centre Hospitalier Universitaire de Nīmes","biomarkers":" IL6 • CXCL13 • IL10 • CD27 • CCL2 • IL17A • MMP9 • IL1B • VCAM1","pipe":"","alterations":" ","tags":["IL6 • CXCL13 • IL10 • CD27 • CCL2 • IL17A • MMP9 • IL1B • VCAM1"],"overall_status":"Completed","enrollment":" Enrollment 165","initiation":"Initiation: 01/02/2018","start_date":" 01/02/2018","primary_txt":" Primary completion: 08/31/2019","primary_completion_date":" 08/31/2019","study_txt":" Completion: 08/31/2019","study_completion_date":" 08/31/2019","last_update_posted":"2019-12-17"},{"id":"e83c17e8-133d-453c-8322-2204032a5fcc","acronym":"CarFlog","url":"https://clinicaltrials.gov/study/NCT04122937","created_at":"2021-01-18T20:08:27.483Z","updated_at":"2024-07-02T16:36:53.224Z","phase":"","brief_title":"Defining Inflammation Related to Peritoneal Carcinomatosis in Women With Ovarian or Colon Cancer.","source_id_and_acronym":"NCT04122937 - CarFlog","lead_sponsor":"University of Pisa","biomarkers":" PD-L1 • BRAF • FGFR1 • CD8 • PD-1 • VEGFA • IL6 • LAG3 • TNFA • CD4 • IL2 • CCL2 • CD68 • TGFB1 • NLRP3","pipe":"","alterations":" ","tags":["PD-L1 • BRAF • FGFR1 • CD8 • PD-1 • VEGFA • IL6 • LAG3 • TNFA • CD4 • IL2 • CCL2 • CD68 • TGFB1 • NLRP3"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 03/30/2019","study_completion_date":" 03/30/2019","last_update_posted":"2019-11-25"},{"id":"9b4893d3-3c8e-45c6-8e96-ccfa788a3528","acronym":"OPTIMAL","url":"https://clinicaltrials.gov/study/NCT04001725","created_at":"2021-07-05T17:23:52.590Z","updated_at":"2024-07-02T16:36:53.762Z","phase":"Phase 2","brief_title":"Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases","source_id_and_acronym":"NCT04001725 - OPTIMAL","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" CCL2","pipe":"","alterations":" ","tags":["CCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • metformin"],"overall_status":"Unknown status","enrollment":" Enrollment 110","initiation":"Initiation: 10/15/2019","start_date":" 10/15/2019","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 03/31/2022","study_completion_date":" 03/31/2022","last_update_posted":"2019-11-13"},{"id":"b54409dc-6ce8-465c-838e-5c152a25bdbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03266159","created_at":"2021-03-26T09:18:25.614Z","updated_at":"2024-07-02T16:37:15.706Z","phase":"Phase 2","brief_title":"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors","source_id_and_acronym":"NCT03266159","lead_sponsor":"GlaxoSmithKline","biomarkers":" KRAS • NRAS • HRAS • NF1 • CCL2","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • HRAS mutation","tags":["KRAS • NRAS • HRAS • NF1 • CCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • molibresib (GSK525762)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 08/19/2020","primary_completion_date":" 08/19/2020","study_txt":" Completion: 08/19/2020","study_completion_date":" 08/19/2020","last_update_posted":"2017-12-08"}]